Extensive preclinical murine cancer models and clinical development efforts have been undertaken for a number of co-inhibitory, or immune checkpoint, receptors that have been characterized as identifying exhausted T cells, including CTLA-4, PD-1, LAG-3, TIM-3, and TIGIT [3–5]. This evidence concerns the gene TIGIT and cancer.